Werkgroep Cardiologische centra Nederland

C-SCADE8 (Completed)

A cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk
Medicine
BI 10773 (empagliflozine)
Population
Diabetes mellitus
Phase
fase III
Starting year
2012
More information
ClinicalTrials.gov

Director of Study

drs. P.R. Nierop (Cardioloog)
Rotterdam, Franciscus Gasthuis